Crystal Clear Supplements took orders for tianeptine and other products FDA calls unapproved new drugs.
What happened
FDA reviewed the company’s website in December 2021, along with its Facebook and Instagram pages and product packaging. FDA found claims that products including tianeptine, phenibut, PEA, Noopept, L-theanine and lutein treat conditions such as depression, anxiety, ADHD, insomnia, cataracts, cancer and diabetes. FDA said these claims make the products unapproved new drugs sold without FDA approval.
What FDA found
The company’s website, social media and packaging claimed the products treat diseases or affect body functions, so FDA treats them as drugs.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The products are not generally recognized as safe and effective for the claimed uses, so they are “new drugs.”
FD&C Act section 201(p), 21 U.S.C. 321(p)The company introduced or delivered these new drugs into interstate commerce without FDA approval.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
What FDA wants
FDA tells the company to notify it in writing within 15 working days of steps taken to address the violations, including how it will prevent recurrence and supporting documents. If the company disagrees, FDA asks for its reasoning and supporting information.
Who should pay attention
- retailers and online marketplaces selling tianeptine or nootropic products
- brands making disease-treatment claims for supplements
- clinicians and consumers encountering tianeptine products
This is a summary. Read the original letter on fda.gov.